Sort by

Send to

Choose Destination

Search results

Items: 5


Breadth of neutralization and synergy of clinically relevant human monoclonal antibodies against HCV genotypes 1a, 1b, 2a, 2b, 2c, and 3a.

Carlsen TH, Pedersen J, Prentoe JC, Giang E, Keck ZY, Mikkelsen LS, Law M, Foung SK, Bukh J.

Hepatology. 2014 Nov;60(5):1551-62. doi: 10.1002/hep.27298. Epub 2014 Oct 2.


Analysis of hepatitis C virus core/NS5A protein co-localization using novel cell culture systems expressing core-NS2 and NS5A of genotypes 1-7.

Galli A, Scheel TK, Prentoe JC, Mikkelsen LS, Gottwein JM, Bukh J.

J Gen Virol. 2013 Oct;94(Pt 10):2221-35. doi: 10.1099/vir.0.053868-0. Epub 2013 Aug 1.


Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus.

Giang E, Dorner M, Prentoe JC, Dreux M, Evans MJ, Bukh J, Rice CM, Ploss A, Burton DR, Law M.

Proc Natl Acad Sci U S A. 2012 Apr 17;109(16):6205-10. doi: 10.1073/pnas.1114927109. Epub 2012 Apr 4. Erratum in: Proc Natl Acad Sci U S A. 2017 Dec 11;:.


Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs.

Gottwein JM, Scheel TK, Jensen TB, Lademann JB, Prentoe JC, Knudsen ML, Hoegh AM, Bukh J.

Hepatology. 2009 Feb;49(2):364-77. doi: 10.1002/hep.22673.


Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization.

Scheel TK, Gottwein JM, Jensen TB, Prentoe JC, Hoegh AM, Alter HJ, Eugen-Olsen J, Bukh J.

Proc Natl Acad Sci U S A. 2008 Jan 22;105(3):997-1002. doi: 10.1073/pnas.0711044105. Epub 2008 Jan 14.

Supplemental Content

Loading ...
Support Center